Valuation: Cosmos Holdings Inc.

Market Cap 10.86M 9.54M 8.87M 8.14M 15.3M 1.05B 15.53M 105M 41.16M 514M 40.78M 39.9M 1.78B P/E 2026 *
20x
P/E 2027 * 2.86x
Enterprise Value 10.86M 9.54M 8.87M 8.14M 15.3M 1.05B 15.53M 105M 41.16M 514M 40.78M 39.9M 1.78B EV / Sales 2026 *
0.13x
EV / Sales 2027 * 0.1x
Free-Float
65.92%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 26/02/2016
Director of Finance/CFO 43 11/11/2020
Chief Operating Officer 56 01/02/2023
Director TitleAgeSince
Director/Board Member 65 28/04/2022
Director/Board Member 58 13/01/2014
Chairman 60 26/02/2016
Change 5-day change 1-year change 3-year change Capi.($)
-5.65%-2.45% - - 10.86M
+1.99%-0.06%+18.13%+108.25% 98.45B
+0.91%-0.21%+45.11%+147.11% 53.41B
-1.05%-3.07%0.00%+257.23% 22.84B
-1.27%-1.38%-13.70%-20.95% 8.13B
-5.96%-5.05%-33.11%-36.73% 7.4B
-0.53%-4.15%-12.84%-31.12% 6.7B
-0.80%-1.73%+20.00%+29.04% 6.17B
-0.52%-2.75%-1.14%+22.46% 5.29B
-0.99%-1.96%-7.05%-8.33% 3.69B
Average -1.39%-3.12%+1.71%+51.89% 23.57B
Weighted average by Cap. +0.71%-1.39%+18.12%+113.19%

Financials

2026 *2027 *
Net sales 84.3M 74.04M 68.86M 63.18M 119M 8.12B 121M 818M 319M 3.99B 316M 310M 13.8B 111M 97.32M 90.5M 83.05M 156M 10.67B 158M 1.07B 420M 5.25B 416M 407M 18.14B
Net income - -
Net Debt - -
Logo Cosmos Holdings Inc.
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
Employees
-

Quarterly revenue - Rate of surprise